Nuveen LLC Buys Shares of 78,145 Candel Therapeutics, Inc. $CADL

Nuveen LLC acquired a new position in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 78,145 shares of the company’s stock, valued at approximately $442,000. Nuveen LLC owned 0.16% of Candel Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Halter Ferguson Financial Inc. raised its holdings in Candel Therapeutics by 1.7% during the first quarter. Halter Ferguson Financial Inc. now owns 693,153 shares of the company’s stock worth $3,916,000 after purchasing an additional 11,819 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Candel Therapeutics by 3.9% during the 4th quarter. Northern Trust Corp now owns 165,021 shares of the company’s stock valued at $1,432,000 after acquiring an additional 6,250 shares in the last quarter. HB Wealth Management LLC grew its holdings in shares of Candel Therapeutics by 8.0% during the 1st quarter. HB Wealth Management LLC now owns 94,300 shares of the company’s stock valued at $533,000 after acquiring an additional 7,000 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Candel Therapeutics by 60.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 83,880 shares of the company’s stock valued at $474,000 after acquiring an additional 31,690 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in Candel Therapeutics by 3.0% during the fourth quarter. Nuveen Asset Management LLC now owns 68,226 shares of the company’s stock valued at $592,000 after buying an additional 2,009 shares in the last quarter. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Price Performance

NASDAQ CADL opened at $4.89 on Friday. The company has a quick ratio of 7.04, a current ratio of 7.04 and a debt-to-equity ratio of 0.01. Candel Therapeutics, Inc. has a 12-month low of $3.79 and a 12-month high of $14.60. The firm’s 50 day moving average is $5.99 and its 200-day moving average is $6.13. The company has a market capitalization of $268.46 million, a PE ratio of -7.09 and a beta of -0.90.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08. Equities research analysts anticipate that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CADL shares. Brookline Capital Management raised Candel Therapeutics to a “strong-buy” rating in a research report on Wednesday, July 9th. Bank of America lowered shares of Candel Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $13.00 to $7.00 in a research report on Wednesday. HC Wainwright raised Candel Therapeutics to a “buy” rating and set a $23.00 price objective for the company in a report on Monday, June 30th. Finally, Wall Street Zen upgraded Candel Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.00.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.